AB Science: New rese
AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease
13 mars 2024 07h59 HE | AB Science
PRESS RELEASE NEW RESEARCH SHOWS THAT MASITINIB LIMITS NEURONAL DAMAGE IN A MODEL OF NEUROIMMUNE-DRIVEN NEURODEGENERATIVE DISEASE THIS IS THE FIRST DEMONSTRATION THAT MASITINIB CAN LOWER SERUM...
Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)
13 mars 2024 07h55 HE | Catalyst Pharmaceuticals, Inc.
AGAMREE® (vamorolone) a Novel Alternative Corticosteroid with Demonstrated Properties in Maintaining Efficacy and a Well-Tolerated Side Effect Profile Available in the U.S. by Prescription for...
How Do Companies Ave
How Do Companies Avert Further Frustration among Neurologists Due to Relyvrio’s (Amylyx) Phase 3 Failure and Donanemab’s (Lilly) FDA delay?
12 mars 2024 15h10 HE | Spherix Global Insights
EXTON, PA, March 12, 2024 (GLOBE NEWSWIRE) -- For neurologists tasked with delivering the distressing diagnosis of Amyotrophic Lateral Sclerosis (ALS) or Alzheimer’s Disease (AD), the upcoming...
Allyx.jpg
Allyx Therapeutics Announces Positive Phase 1b Multiple Ascending Dose Data and Advances ALX-001 to Patients
11 mars 2024 08h05 HE | Allyx Therapeutics Inc.
Allyx Therapeutics Announces Positive Phase 1b Multiple Ascending Dose Data and Advances ALX-001 to Patients
logo 600X600.png
Global Sodium Channel Blockers Market to Reach US$ 9.96 Billion by 2030, Rising at a CAGR of 8.5% | Report by CoherentMI
07 mars 2024 08h11 HE | CMI
Burlingame, March 07, 2024 (GLOBE NEWSWIRE) -- CoherentMI published a report, titled, Global Sodium Channel Blockers Market was valued at US$ 5.64 Billion in the year 2023 and is anticipated to...
Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE
27 févr. 2024 08h03 HE | Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on...
Neurologists Report
Neurologists Report Frustration with Efficacy and Logistical Issues Around Eisai/Biogen’s Leqembi, According to Spherix Global Insights Neurologist Survey
22 févr. 2024 15h04 HE | Spherix Global Insights
EXTON, PA, Feb. 22, 2024 (GLOBE NEWSWIRE) -- The 2023 announcement of newly approved disease-modifying therapy (DMT) Leqembi (lecanemab) for Alzheimer’s Disease (AD) sparked eager anticipation...
Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology
21 févr. 2024 09h00 HE | Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused...
Alterity.png
Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting
20 févr. 2024 10h25 HE | ALTERITY THERAPEUTICS LIMITED
– Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease to be Presented at International Conference – – Baseline Biomarker Data to be Presented from Ongoing ATH434-201 Phase 2...
Parkinson’s Disease
Parkinson’s Disease Patient Identification and Education Will Need to Improve When New Disease Modifying Therapies Are Approved, According to Spherix Global Insights
16 févr. 2024 10h40 HE | Spherix Global Insights
EXTON, PA, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Millions of people worldwide are affected by Parkinson’s disease (PD), prompting the need for effective disease-modifying therapies (DMTs) to target this...